@article{95872,
  keywords = {Erythema nodosum leprosum, apremilast, chronic ENL, recurrent ENL, type-2 lepra reaction},
  author = {Narang T and Ashraf R and Kaushik A and Dogra S},
  title = {Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: A prospective single centre pilot study.},
  abstract = {<p>Recurrent or chronic erythema nodosum leprosum (ENL) is result of immunological reactions in leprosy resulting in significant morbidity and disability for the patients. It is a difficult condition to manage as patients require prolonged courses of high-dose prednisolone with risks of adverse effects (AEs), such as hypertension, diabetes or osteoporosis and steroid dependency along with immunosuppression. Steroid sparing agents like thalidomide, clofazimine, minocycline, cyclosporine, pentoxyfilline, azathioprine and methotrexate have been used with variable success rates.</p>},
  year = {2021},
  journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
  month = {08/2021},
  issn = {1468-3083},
  doi = {10.1111/jdv.17585},
  language = {eng},
}